semaglutide peptide vial (GLP-1) Research Peptide of the Week: Semaglutide

shER36-2: GCGTTGCATCATAACATAAGC

Legumes, nuts, seeds, and whole grains are the best plant-based options

What Happens After Stopping GLP-1 Medications

Still, real-world data shows only about 39.1% of semaglutide users took 80% of their doses over 12 months

The Core Benefits of Microdosing Liver and Cardiovascular Protection A 72-week trial found 40% of patients achieved resolution of fatty liver disease without worsening fibrosis. In animal models, GLP-1s suppress fat production in the liver and reduce inflammation. Tirzepatide at low doses showed particularly strong cardiovascular benefits, with meaningful improvements across multiple lipid markers linked to heart disease risk. Cholesterol storage forms increased far less with tirzepatide, and harmful lipids like ceramides showed minimal increase compared to placebo

It also enables cold-chain monitoring of GLP-1 medicines by integration of the necessary systems